text:
Key Figures ,499 17, ,389 8, % +11% +10% +10% +2% +8% 326,642 82, % +2.4% Group sales. Core operating profit
- Tiffany Jean Clark
- 3 years ago
- Views:
1 Annual Report
2 Key Figures 2012 Group sales Core operating profit Core earnings per share Operating free cash flow R & D investment Dividend 2 45,499 17, ,389 8, millions of CHF millions of CHF CHF millions of CHF millions of CHF CHF +4% +11% +10% +10% +2% +8% (CER) 1 (CER) (CER) (CER) (CER) (CER) Total Shareholder Return 2012 The value of CHF invested 1/1/2012, for the period ending 31/12/ Dec Mar Jun Sep Dec Roche GS, Price = Roche B, Price = Peer Set Index Patients on clinical trials Number of employees 4 1 CER: Constant exchange rates (average full-year 2011). 2 Proposed by the Board of Directors. 3 Prices translated at constant CHF exchange rates: USD=0.90; EUR=1.20; 100 JPY=1.10; GBP= Full-time equivalents. 326,642 82,089 patients employees +10.4% +2.4%
3 Key Events 2012 Roche Group 3% At the Roche Annual General Meeting in 2012, shareholders authorised a 3% dividend increase to CHF 6.80 per share and non-voting equity. It was the company s 25 th dividend increase in as many years. Management changes: Daniel O Day, former Head of Roche Diagnostics, was appointed the new Head of Roche Pharma. Roland Diggelmann has assumed the position of Head of Roche Diagnostics. Daniel O Day Roland Diggelmann Roche continued to streamline its research and development activities, taking the decision to close its site in Nutley, New Jersey, USA. The respective R & D activities are being consolidated in Switzerland and Germany. Our late-stage pipeline made considerable progress in 2012, with 11 out of 14 clinical trials delivering positive results, underpinning the strength of our innovation strategy. Pharmaceuticals The FDA approved Erivedge (vismodegib), a first-in-class Hedgehog Pathway Inhibitor for adults with advanced basal cell carcinoma. The FDA approved Perjeta (pertuzumab) for patients with HER2-positive metastatic breast cancer. This new personalised medicine gives patients more time without their disease worsening. New data from the Phase III EMILIA study showed that Roche s trastuzumab emtansine (T DM1) significantly improved survival of people with HER2-positive metastatic breast cancer. Roche has filed for approval at the FDA and the EMA. After the second interim data analysis of the dal-outcomes trial, Roche decided to discontinue the development of dalcetrapib, a medicine to lower cardiovascular risks.
4 Corporate Sustainability In 2012 we reduced our water consumption by 8.6% and our greenhouse gas emissions by 2.6%. With this, we are well on track to reach our five-year goal of a 10% improvement in efficiency by The second Transnet- Phelophepa Healthcare Train was inaugurated in South Africa. Roche doubled its support, now reaching over 550,000 people a year in rural South Africa through the train s various services. Roche has been recognised as a great place to work, achieving top rankings in prestigious award listings worldwide in Roche has been named Healthcare Supersector Leader in the Dow Jones Sustainability Indexes (DJSI) for the fourth consecutive year. The ranking is a confirmation of Roche s commitment to long-term sustainable value creation. Diagnostics New US guidelines recognise the benefit of genotyping the human papillomavirus (HPV) 16 and 18, the principal causes of cervical cancer in women. The FDA cleared the Accu-Chek Combo system, Roche s new interactive insulin pump system for people with diabetes, and the Accu-Chek Nano SmartView system. Roche Applied Science and Diabetes Care initiated restructuring measures to sustain long-term profitability. Roche launched GUIDE-IT, a clinical trial involving the cardiac marker NT-proBNP to guide therapy in heart failure patients.
5 The value of innovation
6 ROCHE AT A GLANCE Who we are At Roche, we focus on fitting treatments to patients through innovative medicines and diagnostic tests. A global leader in innovation Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics countries 18 research centres #1 in biotech A sustainable company We are committed to sustainability and to running our business in a way that is ethical, responsible and creates long-term value. 18,000,000 patients treated 1 326,642 patients in clinical trials #1 in oncology #1 in in vitro diagnostics in A great workplace We are driven by a shared set of standards of integrity, the courage to reach beyond boundaries and a passion for what we do. 82,089 employees 2 26 manufacturing sites #1 hospital market What we do Pharmaceuticals We are the world s largest biotech company with a product portfolio of truly differentiated therapies and a robust pipeline of investigational new medicines. Sales by therapeutic area 2012 (CER) 3 61% Oncology (+9%) 9% Virology (+14%) 9% Inflammation/Autoimmune/ Transplantation (+5%) 5% Metabolism/Bone ( 23%) 4% Ophthalmology ( 8%) Diagnostics We are the global leader in in vitro diagnostic testing for early detection, evaluation and monitoring of disease. We are also a frontrunner in the management of diabetes. Sales by business area 2012 (CER) 3 51% Professional Diagnostics (+8%) 25% Diabetes Care ( 4%) 11% Molecular Diagnostics (+4%) 7% Applied Science ( 3%) 6% Tissue Diagnostics (+12%) 3% Respiratory diseases (+9%) 3% Cardiovascular diseases (+6%) 2% Renal anemia ( 16%) 2% Central nervous system (+1%) 1% Infectious diseases ( 1%) 1% Other therapeutic areas ( 14%) Pharmaceuticals Sales 35.2 billion CHF Diagnostics Sales 10.3 billion CHF Roche Group Sales 45.5 billion CHF 1 With one of Roche s 25 top-selling products. 2 Full-time equivalents (FTE). 3 CER: Constant Exchange Rates (average full-year 2011).
7 Our strategic priorities Patients in need We strive to help patients in need with truly differentiated diagnostics and medicines. Our focus lies in five disease areas with unmet medical need, oncology, inflammation, infectious disease, metabolism and the central nervous system. 29 million cancer 70 million hepatitis C 24 million schizophrenia 235 million asthma 346 million diabetes Personalised Healthcare Personalised Healthcare at Roche is about providing the right therapy for the right group of patients at the right time. We provide medicines and diagnostics that optimise patient care, enabling tangible improvements in health, quality of life and survival. Pharmaceuticals PERSONALISED HEALTHCARE Diagnostics Excellence in science Roche is a highly innovative healthcare company, with a robust R & D foundation. We have three autonomous research units, as well as 150 partnerships all over the world, to foster diversity of research and translate science into medicines. IN-HOUSE CUTTING EDGE SCIENCE OPTIMAL RESOURCE ALLOCATION EXTERNAL INNOVATION Innovative pricing models Roche aims to bring its medicines and diagnostic tests to as many patients in need as possible. To do this, we explore innovative pricing models and patient access schemes targeted to individual markets. ESTAbLISHED markets Pressure from more active payers EMERGING markets Build-up of healthcare systems with tight cost parameters Stakeholder value By discovering and developing innovative products, we aim to provide value to all our stakeholders, be they patients, doctors, employees, investors or society as a whole. PATIENTS value for ALL stakeholders EMPLOYEES SHAREHOLDERS PROVIDERS
8 TOP-SELLING pharmaceuticals in millions of CHF 6,707 5,889 5,764 1,649 1,523 Product MabThera/ Rituxan Herceptin Avastin Pegasys Xeloda Sales growth (CER) 1 +9% +11% +6% +12% +9% Active substance rituximab trastuzumab bevacizumab peginterferon alfa-2a capecitabine Indications non-hodgkin s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, ANCA-associated vasculitis HER2-positive breast cancer, advanced HER2- positive stomach cancer colorectal cancer, breast cancer, non-small cell lung cancer, kidney cancer, ovarian cancer, glioblastoma hepatitis B and C colorectal cancer, colon cancer, breast cancer 1 CER: Constant exchange rates (average full-year 2011).
9 TOP-SELLING diagnostics in millions of CHF Accu-Chek Nano SmartView cobas e 602 cobas c 502 cobas TaqMan 48 Ventana IHC reagents 2,346 2,321 1, Product Accu-Chek monitoring systems cobas e modules, Modular Analytics, Elecsys cobas c modules, Modular Analytics, Cobas Integra Cobas AmpliPrep/ Cobas TaqMan immunohistochemistry and in situ hybridisation Sales growth (CER) 1 5% +15% +5% +2% +13% Market segment Blood glucose monitoring Immunoassays Clinical chemistry Virology (hepatitis B, hepatitis C, HIV) Advanced tissue staining Business area Diabetes Care Professional Diagnostics Professional Diagnostics Molecular Diagnostics Tissue Diagnostics
10 Special Feature Roche Business Report _99_Roche_AR12_Onco_Feature_ENG.indd :01:39 The Value of Innovation Roche is a global leader in innovation for medicines and diagnostic testing. This annual report highlights how innovation brings value to patients, prescribers, healthcare reimbursement and society as a whole A possible new medicine for HER2-positive metastatic breast cancer A new generation of cancer treatment Actemra/Roactemra Relief for the agony of childhood arthritis High-sensitivity cardiac test Precise testing for life or death decisions Accurate diagnosis and personalised healthcare Focusing healthcare budgets on targeted treatments Working with the insurance industry in China Improving health insurance coverage for cancer patients cobas HPV and CINtec tests Better screening for cervical cancer Special Feature From mining to biotech - Roche Penzberg Innovation creating value for the local economy 50 years of cancer research at Roche The fight against cancer goes on Innovation in the pharmaceutical industry A lasting contribution to world health The fight against cancer goes on 50 years of cancer research at Roche One in three people will develop cancer during their lifetime. And yet the challenge to find a cure remains elusive. One of the reasons it is so difficult to treat is that cancer is, strictly speaking, not just one disease but a group of different diseases. So far, over 250 different types have been identified. What cancers have in common though, is that they are all caused by the uncontrolled proliferation of human cells. Roche has been at the forefront of cancer research for decades and is today the leading pharmaceutical and diagnostic company in the field. Well over 50 years ago, Robert Duschinsky (see picture) from Nutley, in collaboration with Charles Heidelberger from the University of Wisconsin, synthesized 5-Fluoro-uracil (5 FU), Roche s first anticancer drug. Although this was considered a breakthrough at the time, it caused severe side effects because it attacks both healthy cells and cancer cells. From the start, our aim was to advance the treatment of cancer. As a result, Roche later developed several successor drugs with the aim of preferentially generating the cytotoxin 5-FU in the tumour itself, and consequently of achieving greater efficacy with fewer side effects. Since those early beginnings, cancer research conducted by Roche and others has provided doctors and patients with better and better medicines and diagnostic agents. Cancer cells, unfortunately, are inventive they discover ways of escaping treatment, often reproliferating at a later stage. Despite tremendous progress in the treatment of cancer, much remains to be done to combat this insidious disease
11 Contents inside cover Key Figures 2012 Key Events 2012 Roche at a Glance 8 Letter from the Chairman 10 Letter from the CEO 12 Management Business Review 20 Group results and outlook 23 Market Environment and Group Strategy Research and Development 38 Highlights of Improving R&D productivity 47 Accessing external innovation 50 Pharmaceuticals pipeline Manufacturing and Procurement 63 Pharmaceuticals manufacturing 65 Diagnostics manufacturing Marketing and Distribution 74 Tailored market strategies 75 Innovative pricing models 66 Quality and compliance 68 Procurement Responsible Business 82 Code of conduct 83 Stakeholder engagement Our People 92 Building a great workplace 94 Attracting and retaining top talent Community Involvement 103 Humanitarian and social projects 104 Science and education 84 Patient safety 87 Contributing to public policy 94 Learning and career development 95 Embracing diversity 104 Arts and culture 105 Community and environment Safety, Security, Health and Environment 110 Improving and monitoring performance 112 Minimising our environmental footprint Corporate Governance, Remuneration Report 124 Corporate Governance 132 Remuneration Report 117 Safeguarding employees and property 118 Pharmaceuticals in the environment Independent Assurance Report
12 Letter to Shareholders from Franz B. Humer Dear Shareholders High levels of public debt, especially in Europe and the United States, and the continued strength of the emerging economies were the two dominant influences on the healthcare sector in 2012, bringing both challenges and opportunities. Overall, it was a demanding year for the industry and one where cost pressure in many markets continued to increase. Notwithstanding these challenges, Roche again posted very good results for the year, with a firm strategy of developing medically differentiated medicines and diagnostic products for diseases in areas of high unmet medical need. Group sales increased 4%, at constant exchange rates, to 45.5 billion Swiss francs (+7% in Swiss francs), with both the Pharmaceuticals and Diagnostics Divisions growing faster than their respective markets. Roche delivered strong growth in the United States and the emerging markets, whilst in Europe we continued to feel pricing pressure from healthcare budget cuts. Our focus on high-value medicines and diagnostic tests, however, meant that, relative to the rest of the industry, our sales in Europe held up well. In general, what we are seeing is an increasing shift from the established markets, especially in Europe, to the faster grow ing emerging market nations in Asia and Latin America, where Roche already records a fifth of its sales. Cancer and cardiovascular disease are now among the leading causes of death in emerging economies and demand for our medicines is rising as a result. We are actively expanding our position in Asia and Latin America, thereby improving global access to our medicines and diagnostics products. We have optimised our organisational structure over the past year, adapting our processes to this changing market environment. A notable move was the closure of the Roche site in Nutley, New Jersey in the United States as part of the conso Roche Business Report 2012 Letters to Shareholders 8
13 lidation of research and early-stage development activities. Closing the site was not an easy decision. Nutley has played a pivotal role in the company s success over the past 80 years. Core operating profit for 2012 again improved significantly, while net income was slightly higher at 9.8 billion Swiss francs, as the good operating performance was offset by costs associated with a number of major restructuring programmes and a higher tax rate. On a comparable basis, core net income was up 10% over the previous-year period at constant exchange rates (+11% in Swiss francs). Another highlight for the year was the Dow Jones Sustainability Indexes naming Roche Supersector Leader for the fourth consecutive year, ranking us as the world s most sustainable healthcare company. Leading the way in personalised healthcare As a leader in personalised healthcare, Roche is uniquely positioned to develop treatments that raise current standards of care and extend and improve the lives of patients. Some 60% of the projects in our pharmaceuticals pipeline are being developed in conjunction with companion diagnostic tests. In 2012 we further strengthened Personalised Healthcare, launching the cancer medicines Perjeta, for breast cancer and Zelboraf, for melanoma, alongside their companion diagnostics. Medical innovation not only benefits patients, but also our partners in the healthcare market, payers, the economy and society in general. Regrettably, in Europe in particular, there continues to be too much focus on costs and short-term thinking, which harbours the risk of missing longer-term opportunities for our economy and society. This longer-term perspective tends to be neglected in the discussions about rising healthcare costs, as does the contribution that pharmaceuticals and diagnostics make to medical progress. Sustainable success and this applies not only to Roche but to business generally requires long-term thinking and forward-looking investments. Innovation is, and will continue to be, the motor driving our long-term success. This success story must be continued through open dialogue between politicians and industry. Board to propose 7.35 Swiss francs dividend for 2012 In view of these good results, the Board of Directors is proposing an 8% dividend increase, to 7.35 Swiss francs per share and non-voting equity security (2011: 6.80 Swiss francs). More than half of net income will be distributed to shareholders as dividends. Subject to your approval, this will be our 26 th dividend increase in as many years. As previously announced, Prof. Bruno Gehrig and Lodewijk J. R. de Vink (both members of the Board of Directors since 2004) have decided not to stand for re-election to the Board of Directors at our next Annual General Meeting. During their many years of service, both have made exceptionally valuable contributions to the growth of our company. We owe them a debt of gratitude. The Board of Directors proposes the election of Dr Severin Schwan, CEO of the Roche Group, as a new member of the Board of Directors of Roche Holding Ltd. This will enable the Board of Directors and Corporate Executive Committee to work together even more closely, which will help promote the growth of the company in today s challenging market environment. The two new Corporate Executive Committee members announced in the second half of 2012 were recruited from within the company: Daniel O Day, former Chief Operating Officer (COO) of the Diagnostics Division, was appointed COO of the Pharmaceuticals Division effective 1 September Roland Diggelmann, former Head of the Asia Pacific region within Roche Diagnostics, was appointed as a new member of the Corporate Executive Committee and Daniel O Day s successor as COO of the Diagnostics Division. In its newly constituted form, the Corporate Executive Committee will continue to progress the Group s current strategic course and sustainably drive Roche s success as a global leader in healthcare. Clinical differentiation is the key to serving patients medical needs in a better, safer and more cost-effective way, which is even more crucial in this increasingly costsensitive environment. Roche will continue to advance its successful strategy of focus and innovation for the benefit of patients, physicians, employees and you, our shareholders. Franz B. Humer Chairman of the Board Letters to Shareholders Roche Business Report
14 Letter to Shareholders from Severin Schwan Dear Shareholders In a difficult market environment, your company delivered a strong performance in 2012, continuing the positive growth trend of recent years. We met all our sales and earnings targets, and importantly, made significant strides in product development. Three new Roche cancer medicines have been approved in the last 18 months and a new cancer drug has also been filed for approval. Before I expand on our advances in research and development, I would first like to summarise our key financial results. Sales in the Pharmaceuticals Division rose 5% at constant exchange rates to 35.2 billion Swiss francs (+7% in Swiss francs), with growth driven by cancer medicines Herceptin, MabThera/Rituxan, Avastin and Zelboraf; as well as our rheumatoid arthritis drug Actemra/RoActemra, Pegasys, our hepatitis C medicine, and Tamiflu. The Diagnostics Division consolidated its global market leadership with sales up 4% to 10.3 billion Swiss francs (+5% in Swiss francs), driven by strong demand from clinical laboratories. Immunoassays, sophisticated blood tests to diagnose a range of diseases, also performed very well, continuing a more than decade-long trajectory of double-digit growth. Core operating profit increased 11% (at constant exchange rates) to 17.2 billion Swiss francs, outpacing sales growth significantly. The Group core operating profit margin rose 2.1 percentage points to 37.7%, driven mainly by productivity gains and cost savings. Core earnings per share a key metric of underlying business performance, which excludes items such as global restructuring charges, amortisation and impairment of intangible assets increased 10% at constant exchange rates, above original expectations. In achieving these results, I would like to thank our employees for their hard work, commitment and professionalism. Their efforts continue to make Roche one of the world s most successful healthcare companies. Roche Business Report 2012 Letters to Shareholders 10
15 Bringing innovation to patients Our development pipeline, a key foundation for Roche s future, also showed healthy growth in 2012 and now has 72 new molecular entities in clinical development. Overall, we had posi tive data from 11 trials for drugs in late-stage clinical testing, strengthening our business with innovative products and securing our future for years to come. The Diagnostics pipeline remains solid, with 55 new products launched in key markets in A significant highlight of 2012 was the extension of Roche s product portfolio for treating the highly aggressive HER2-positive form of breast cancer. Backed by decades of research, Roche is currently leading a wave of innovative developments to combat these severe tumours. Our new breast cancer drug Perjeta was approved by the US Food and Drug Administration in June 2012 after priority review. Therapy combinations designed to overcome treatment resistance whilst targeting multiple pathways in cancer are becoming more and more important. Clinical trials show that patients treated with Perjeta, Herceptin and chemotherapy live significantly longer than those receiving standard therapy and with our companion diagnostic tests, patients who are likely to respond to these targeted medicines can be quickly identified. Adding to this group of medicines, we have filed for regulatory approval of a new drug, an antibody drug conjugate known as trastuzumab emtansine (T DM1). Roche is at the forefront of developing antibody drug conjugates (ADCs), nine of which are currently in clinical development. ADCs combine the specificity of antibodies with the power of chemotherapy, targeting the cancer cells directly and significantly reducing the side effects of systemic chemotherapy. The risk of death for breast cancer patients receiving T DM1 was shown in trials to be 32% lower than for those receiving standard treatment. Promising drugs are also currently being studied in global programmes in chronic lymphocytic leukemia and non-hodgkin s lymphoma. They have the potential to improve on MabThera/ Rituxan, the current standard of care in fighting hematological tumours. Maximising R & D productivity Operationally, we are restructuring our pharmaceutical research and development activities in order to better allocate resources and further improve our efficiency. This has resulted in the difficult decision to close the Roche site in Nutley, New Jersey. The resulting savings from the site consolidation and related infrastructure costs will allow us to reallocate resources to our growing number of clinical programmes, whilst maintaining stable R & D expenditure overall. I am aware of the impact this has had on all the employees affected by the closure, and on their families. We are providing the affected employees with financial support and professional advice to help prepare them for new job opportunities. We will establish a Translational Clinical Research Center in New York, keeping our presence on the East Coast of the United States. The Center will accommodate over 200 employees and support clinical trials and early development programmes, as well as continue collaborations with academic institutions and biotech companies. Going forward, I am convinced that we have taken the right measures and we will continue to see the benefits coming through. Overall, for 2013, we are expecting to achieve sales growth at constant exchange rates in line with the Roche Group s results for the previous year. We target core earnings per share to grow ahead of sales. Based on this outlook, we antici pate being able to raise our dividend again in Severin Schwan Chief Executive Officer In addition to oncology, Roche is also focusing on other disease areas of high unmet medical need, in the field of neuroscience for Alzheimer s disease and schizophrenia, as well as on metabolic, inflammatory and autoimmune diseases. Despite the recent decision to terminate the dalcetrapib clinical programme, Roche remains committed to developing medicines for patients with cardiovascular disease and diabetes. Discovering and developing new drugs means taking calculated risks there is no other road to real innovation. Letters to Shareholders Roche Business Report
16 Board of Directors Dr Franz B. Humer Prof. Bruno Gehrig André Hoffmann Dr Andreas Oeri Prof. Pius Baschera Prof. Sir John Irving Bell Paul Bulcke William M. Burns Lodewijk J. R. de Vink Dr Christoph Franz Dame DeAnne Julius Dr Arthur D. Levinson Peter R. Voser Prof. Beatrice Weder di Mauro Board of Directors per 31 December 2012 Roche Business Report 2012 Management 12
17 Board of Directors Name (year of birth) Term ends First elected Board of Directors Dr Franz B. Humer (1946) D *, E Chairman Prof. Bruno Gehrig (1946) C *, D, E Vice-Chairman André Hoffmann (1958) A, C, D, E Vice-Chairman Prof. Pius Baschera (1950) A, E Prof. Sir John Irving Bell (1952) B, E Paul Bulcke (1954) B, E William M. Burns (1947) A, E Lodewijk J. R. de Vink (1945) B, E Dr Christoph Franz (1960) C, E Dame DeAnne Julius (1949) B *, E Dr Arthur D. Levinson (1950) C, E Dr Andreas Oeri (1949) A *, E Peter R. Voser (1958) C, E Prof. Beatrice Weder di Mauro (1965) B, E Secretary to the Board of Directors Dr Gottlieb A. Keller (1954) Honorary Chairman of the Board of Directors Dr Fritz Gerber (1929) A Corporate Governance and Sustainability Committee. B Audit Committee. C Remuneration Committee. D Presidium/Nomination Committee. E Non-executive director. * Committee chairperson. Board of Directors At the 94 th Annual General Meeting (AGM) of Roche Holding Ltd, on 6 March 2012, shareholders re-elected John I. Bell, André Hoffmann and Franz B. Humer as members of the Board of Directors for the term of two years as provided by the Articles of Incorporation. Management Roche Business Report
18 Corporate Executive Committee Dr Severin Schwan Daniel O Day Roland Diggelmann Dr Alan Hippe Silvia Ayyoubi Dr Gottlieb A. Keller Dr Richard Scheller Dr Mike Burgess 1 Dr Sophie Kornowski-Bonnet Osamu Nagayama Dr Stephan Feldhaus Corporate Executive Committee per 31 December 2012 Roche Business Report 2012 Management 14
19 Corporate Executive Committee Name (year of birth) Position Corporate Executive Committee Dr Severin Schwan (1967) CEO of the Roche Group Dr Alan Hippe (1967) Chief Financial and IT Officer Daniel O Day (1964) COO Division Roche Pharmaceuticals Roland Diggelmann (1967) COO Division Roche Diagnostics Dr Gottlieb A. Keller (1954) General Counsel Silvia Ayyoubi (1953) Head Group Human Resources Enlarged Corporate Executive Osamu Nagayama (1947) Chairman and CEO Chugai Committee Dr Richard Scheller (1953) Head Genentech Research and Early Development (gred) Dr Mike Burgess 1 (1962) Head Roche Pharma Research and Early Development (pred) (ad interim) Dr Stephan Feldhaus (1962) Head Group Communications Dr Sophie Kornowski-Bonnet (1963) Head Roche Partnering Secretary to the Corporate Executive Committee Per-Olof Attinger (1960) Statutory Auditors of Roche Holding Ltd KPMG Klynveld Peat Marwick Goerdeler SA (reporting years ) KPMG AG (since 2009) Auditor in charge: John A. Morris ( ) Ian Starkey (since 2011) Chief Compliance Officer Dr Urs Jaisli (1956) 1 John C. Reed will assume the position of Head of Pharma Research and Early Development (pred) on 2 April 2013 and will become a member of the Enlarged Corporate Executive Committee. Corporate Executive Committee Sophie Kornowski-Bonnet was appointed Head of Roche Partnering and joined the Enlarged Corporate Executive Committee on 1 February Mike Burgess assumed the ad-interim position of Head of Pharma Research and Early Development (pred) on 1 July 2012 and became a member of the Enlarged Corporate Executive Committee. Daniel O Day was appointed COO of the Roche Pharmaceuticals Division and Roland Diggelmann, COO of the Roche Diagnostics Division. Both appointments were effective from 1 September Management Roche Business Report
20 The value of innovation A possible new medicine for HER2-positive metastatic breast cancer A new generation of cancer treatment When treating cancer, oncologists are looking for medicines that will deliver the best results with the fewest side effects. An advance in this area could mean that physicians may soon be able to prescribe a treatment that is even more effective and better tolerated than existing therapies. Our late-stage drug candidate, trastuzumab emtansine (T DM1), is able to deliver a potent dose of chemotherapy to the cancer cells because the chemotherapy is linked to an active antibody. This could potentially reduce the side effects of traditional therapy. Developing a drug that can limit the impact of chemotherapy provides true value for both prescribers and patients. Prof. Paul Ellis, Guy's Hospital, was an investigator in the EMILIA trial: I very much hope that our patients will actually need less of the traditional systemic cytotoxic chemotherapy and as such be exposed to less in the way of the debilitating side effects normally associated with those agents. I think apart from the effectiveness that is one of the real legacies of these new types of treatments, such as T DM1. How the T DM1 antibody drug conjugate works: The drug is made up of trastuzumab¹, a chemotherapy called DM1, and a linker. The linker connects trastuzumab and DM1. T DM1 binds to the HER2-positive cancer cells, and is thought to block out-of-control signals that make the cancer grow while also calling on the body s immune system to attack the cancer cells. Once T DM1 is absorbed into those cancer cells, it is designed to destroy them by releasing the DM1. T DM1 Potent cytotoxic agent (DM1) Stable linker Monoclonal antibody (trastuzumab) T DM1 1 binds to the HER2 receptor on the tumour cell surface, initiating several antitumour activities before being absorbed into the cell. Once inside the cell, T DM1 breaks down and releases the active form of DM1 2. DM1 then binds to a protein structure that plays a key role in cell division 3. This prevents the cell from dividing and ultimately results in cancer cell death More on the web: 1 Trastuzumab is the active ingredient in Herceptin. Roche Business Report 2012 The value of innovation 16
+4.7 +4.3 +3.9 +6.2 +4.5. Net debt (6,708) (10,599) 37 38. Capitalisation 39,884 41,340 4 +2 Debt 18,643 24,590 24 22 Equity 21,241 16,750 +27 +37
Finance Report Finance in brief Key results Sales CER growth % Core operating profit margin, % of sales Pharmaceuticals 2013 +6.7 2012 +4.7 44.4 44.0 Diagnostics 2013 2012 +4.3 +3.9 20.8 21.3 Group 2013More information
Annual General Meeting of Roche Holding Ltd 2 March 2010
r Annual General Meeting of Roche Holding Ltd 2 March 2010 Address by Severin Schwan CEO of the Roche Group (Check against delivery.) Address by Severin Schwan Page 2 of 14 Ladies and Gentlemen, FellowMore information
Roche reports solid sales growth in the first quarter of 2016
Media Release Basel, 19 April 2016 Roche reports solid sales growth in the first quarter of 2016 Group sales up 4% 1 at constant exchange rates, 5% in Swiss francs Pharmaceuticals Division sales increaseMore information
+0.1 +3.9 +5.9 +4.5 +1.4
Finance Report Finance in brief Key results Sales CER growth % Core operating profit margin, % of sales Pharmaceuticals 2012 +4.7 2011 +0.1 44.0 40.9 Diagnostics 2012 2011 +3.9 +5.9 21.3 22.4 Group 2012More information
FDA grants Roche s Perjeta regimen Priority Review for use before surgery in HER2-positive early-stage breast cancer
Media Release Basel, 2 July, 2013 FDA grants Roche s Perjeta regimen Priority Review for use before surgery in HER2-positive early-stage breast cancer Application follows proposed new FDA pathway designedMore information
Core results Research and development 8,913 8,700 +2 +4 18.8 18.6 Core operating profit 17,636 17,904 1 +3 37.2 38.3 Core EPS (CHF) 14.29 14.
Finance Report 2014 Finance in brief Key results Sales CER growth % Core operating profit margin, % of sales Pharmaceuticals 2014 +4.5 2013 +6.7 43.6 44.4 Diagnostics 2014 2013 +6.4 +4.3 19.5 20.8 GroupMore information
Roche Committed to innovation and profitable growth. Dr. Karl Mahler Head of Investor Relations. London, July 2011
Roche Committed to innovation and profitable growth Dr. Karl Mahler Head of Investor Relations London, July 2011 2 This presentation contains certain forward-looking statements. These forward-looking statementsMore information
Emerging market opportunities for Roche. Luke Miels, Head of Asia-Pacific Roche Pharmaceuticals
Emerging market opportunities for Roche Luke Miels, Head of Asia-Pacific Roche Pharmaceuticals International region overview Eastern Europe & Middle East Asia Pacific Africa Latin America Market driversMore information
INNOVATION From prevention to lifeextending
Annual Report 2014 P E R F O R M A N C E Reporting solid results, Roche will propose an increase of the dividend for the 28 th year running. Discover how the new Chairman, Christoph Franz, plans to buildMore information
Diagnostics Division. Roland Diggelmann COO Roche Diagnostics. Picture
Diagnostics Division Roland Diggelmann COO Roche Diagnostics Picture HY 2013: Roche Group highlights HY 2013 performance Strong Pharma performance, driven by US; solid growth for Diagnostics 12% core EPSMore information
91,747 employees in over 100 countries
Roche in Brief 2015 Roche Who we are Who we are Roche Who we are 91,747 employees in over 100 countries CHF 48.1 bn in Group sales in 2015 # 1 in biotech, oncology, in vitro diagnostics and hospital marketMore information
Roche reports strong sales growth in the first quarter of 2015. medicines, Avastin, MabThera/Rituxan) and immunology (Actemra/RoActemra, Xolair)
Media Release Basel, 22 April 2015 Roche reports strong sales growth in the first quarter of 2015 Group sales up 5% at constant exchange rates (CER) 1, 3% in Swiss francs Pharmaceuticals Division salesMore information
Nine-month sales show continued double-digit growth significantly above the market average
Investor Update Basel, 14 October 2004 Nine-month sales show continued double-digit growth significantly above the market average Roche Group Sales in core businesses up by 14%* to 21.9 billion Swiss francsMore information
TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers andMore information
Roche facts & figures for U.S. investors
Roche facts & figures for U.S. investors About Roche Founded in 1896, headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals andMore information
INNOVATION From prevention to lifeextending
Annual Report 2014 P E R F O R M A N C E Reporting solid results, Roche will propose an increase of the dividend for the 28 th year running. Discover how the new Chairman, Christoph Franz, plans to buildMore information
F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland Half-Year Report 2012 All trademarks are legally protected. www.roche.com 2012
Half-Year Report 2012 Finance in brief Key interim results Sales CER growth % Core operating profit margin, % of sales Pharmaceuticals 2012 +3.8 2011 1.3 45.3 43.9 Diagnostics 2012 2011 +5.1 +5.2 19.9More information
Special Feature: Growth Model of an Agile Company
Special Feature: Growth Model of an Agile Company 15 Sysmex s Global Strategy From the time of its establishment, Sysmex has followed a steady growth trajectory, and the Group now provides products andMore information
FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurableMore information
Innovative people need room to breathe
92/93 Arthur D. Little How important is the protection of intellectual property to sustaining innovation in your business? Schwan Without patents there would be no innovation in our industry. Patents areMore information
Life writes the questions We pursue the answers
Life writes the questions We pursue the answers Life writes the questions. 1 What will help me? Can I have hope? When will the others notice? How much life is six months? How bad can it get? Am I alone?More information
F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland. All trademarks are legally protected. www.roche.com. Finance Report 2015. Roche
F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland 2016 All trademarks are legally protected. www.roche.com Roche Finance Report 2015 0 000 000 E Finance Report 2015 Finance in brief Key results Sales CERMore information
Key figures 2015 CHF millions % change
Media Release Basel, 28 January 2016 Roche reports strong results in 2015 Group sales increased by 5% 1 at constant exchange rates, 1% in Swiss francs Pharmaceuticals Division sales up 5%, driven by oncologyMore information
Roche on track for full-year targets good sales growth in first quarter
Investor Update Basel, 12 April 2012 Roche on track for full-year targets good sales growth in first quarter Group sales rise 2% at CER 1 (-1% in Swiss francs; +1% in US dollars) to 11.0 billion SwissMore information
Key facts Corporate Governance and Remuneration Report. Corporate Governance and Remuneration Report
Key facts Corporate Governance and Remuneration Report Corporate Governance and Remuneration Report 140 Roche Annual Report 2014 Corporate Governance and Remuneration Report Key facts After its foundationMore information
Roche delivers continued growth in the first half of 2016
Media Release Basel, 21 July 2016 Roche delivers continued growth in the first half of 2016 Group sales increased by 5% 1 at constant exchange rates, 6% in Swiss francs Pharmaceuticals Division sales upMore information
What Lies Ahead? Trends to Watch: Health Care Product Development in North America
What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into theMore information
Time to stop wasting time Getting novel medicines to patients. 4 th World Health Summit, Berlin Severin Schwan, 22 October 2012
Time to stop wasting time Getting novel medicines to patients 4 th World Health Summit, Berlin Severin Schwan, 22 October 2012 Pharma Business Model for Innovation Challenges Summary Pharma Industry UnlimitedMore information
Roche Holdings, Inc. Annual Report 2013
r Roche Holdings, Inc. Annual Report 2013 1 Roche Holdings, Inc. Consolidated Financial Statements Contents Management Report 2 Review for the year ended December 31, 2013 Principal risks and uncertaintiesMore information
Our values help us to create added value in a sustainable way. Sustainability includes fostering and retaining our most talented employees
Our values help us to create added value in a sustainable way Sustainability includes fostering and retaining our most talented employees 32 Sustainability Report 2004 Creating value through sustainableMore information
Annual Report on Form 20-F
Annual Report on Form 20-F 2 Teva at a Glance Founded in 1901 by three young pharmacists, today Teva Pharmaceutical Industries Ltd. is a leader in the global pharmaceutical industry, providing medicinesMore information
Roche in Switzerland Innovation is our home
Roche in Switzerland Innovation is our home Roche s sites in Switzerland in context Roche was founded by Fritz Hoffmann-La Roche on 1 October 1896. He was one of the first people to recognise that majorMore information
Contents. Overview 02 Who we are 04 What we do 06 2015 highlights 08 Chairman s shareholder letter 14 CEO s shareholder letter
Annual Report 2015 P A T I E N T S Positive late-stage clinical study results on our investigational medicine ocrelizumab in multiple sclerosis give hope to people living with this disease who need moreMore information
Media Release. Roche posts strong first-half results. Úten morgen her speck! Basel, 25 July 2013
Media Release Úten morgen her speck! Basel, 25 July 2013 Roche posts strong first-half results Group sales 5% 1 higher at 23.3 billion Swiss francs Core EPS 12% higher at 7.58 Swiss francs; net incomeMore information
F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland Half-Year Report 2013 All trademarks are legally protected. www.roche.com 2013
Half-Year Report 2013 Finance in brief Key interim results Sales CER growth % Core operating profit margin, % of sales Pharmaceuticals 2013 +5.7 2012 +3.8 46.9 45.3 Diagnostics 2013 2012 +2.6 +5.1 21.1More information
Investor Update. Roche posts very strong interim results. Basel, 20 July 2005
Investor Update Basel, 20 July 2005 Roche posts very strong interim results Roche Group Group sales up 17%. Pharmaceutical sales grow three times faster than the global market Operating profit rises 30%,More information
A Letter from MabVax Therapeutics President and Chief Executive Officer
A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for theMore information
ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o CombinationMore information
M I N U T E S. The Chairman of the Board, Dr Franz B. Humer, opened the meeting at 10.30 a.m. and took the chair.
Translated from the German M I N U T E S of the 94th Annual General Meeting of the Shareholders of ROCHE HOLDING LTD, Basel, held at 10.30 a.m. on 6 March 2012 at the Convention Centre, Basel Trade FairMore information
Employees Employees as at 31 August 53 44 20.5 Employees average during the reporting period 52 44 18.2
9M 2007 9M 2006 Change in % Earnings key figures in EUR 000 Other operating income 2,158 966 123.4 Operating expenses (19,486) (13,149) 48.2 of which research and development (16,606) (10,527) 57.8 OperatingMore information
Cancer Monoclonal Antibodies Market Forecast to 2017
RNCOS Page 1 Table of Contents 1. Analyst View 2. Research Methodology 3. The Global Burden of Cancer 3.1 Cancer - A Leading Cause of Death 3.2 Current and Future Cancer Cases: By Type and Geography 3.3More information
Enhancing Value With Financial & Operational Excellence
Enhancing Value With Financial & Operational Excellence Robert Hombach CFO & COO Enhancing Value With Financial & Operational Excellence Growing Sales & Earnings Generating value in attractive marketsMore information
Roche Diagnostics. Daniel O Day COO Roche Diagnostics. Bernstein 8 th Annual Decisions Conference, London September 20, 2011
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,More information
Roche Diagnostics Driving Personalized Healthcare
r his presentation contains certain forward-looking statements. hese forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,More information
Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019
Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitiveMore information
Financial Information
Financial Information Solid results with in all key financial metrics of 23.6 bn, up 0.4% like-for like Adjusted EBITA margin up 0.3 pt on organic basis Net profit up +4% to 1.9 bn Record Free Cash FlowMore information
We Innovate Healthcare
Part 2 Roche Annual Report 2007 Finance Report We Innovate Healthcare We Innovate Healthcare As a research-intensive healthcare company, Roche discovers, develops and provides innovative diagnostic andMore information
Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies
Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Fern Barkalow, Ph.D, Senior Analyst, Oncology Citeline One of the biggest challenges facing biosimilar drug developers isMore information
Media Release. Basel, 11 June 2009. RA patients with enhanced response identified
Media Release Basel, 11 June 2009 New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis RA patientsMore information
Diagnostics: Growth through innovation and Personalised Healthcare. Daniel O Day, COO Roche Diagnostics
Diagnostics: Growth through innovation and Personalised Healthcare Daniel O Day, COO Roche Diagnostics Roche Diagnostics portfolio overview Industry leading businesses covering the entire IVD spectrumMore information
FDA grants Roche s cancer immunotherapy Tecentriq (atezolizumab) accelerated approval for people with a specific type of advanced bladder cancer
Media Release Basel, 19 May 2016 FDA grants Roche s cancer immunotherapy Tecentriq (atezolizumab) accelerated approval for people with a specific type of advanced bladder cancer First and only anti-pd-l1More information
Management s Discussion and Analysis
Management s Discussion and Analysis 6 Financial Policy Sysmex regards increasing its market capitalization to maximize corporate value an important management objective and pays careful attention to stableMore information
Avastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leadingMore information
Groundbreaking Collaborative Clinical Trial Launched
Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)More information
REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for HER2-Positive Breast Cancer in China MarketMore information
New York Bio Conference 2016. Mark J. Alles Chief Executive Officer
New York Bio Conference 2016 Mark J. Alles Chief Executive Officer Great Progress AGE 72 World Life Expectancy 2005-2014* 17 new drugs for rare diseases 71.5 71 Two new MS drugs First drug to target rootMore information
2019 Healthcare That Works for All
2019 Healthcare That Works for All This paper is one of a series describing what a decade of successful change in healthcare could look like in 2019. Each paper focuses on one aspect of healthcare. ToMore information
Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022
Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis andMore information
Roche Finance Report Roche
2010 Roche Finance Report Table of contents Roche Group 2 Finance in brief 2 Finance 2010 in brief 3 Financial Review 4 Roche Group Consolidated Financial Statements 34 Notes to the Roche Group ConsolidatedMore information
Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry
Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Tariq Sadat PhD Candidate School of Economics, Finance and Marketing, RMIT University, Australia RoslynMore information
Three months ended 31 March
Media Release Basel, 15 April 2010 Excellent growth in first quarter of 2010 Group sales up 9% in local currencies to 12.2 billion Swiss francs in first three months (+6% in Swiss francs, +15% in US dollars).More information
Gastric Cancer. Brochure More information from http://www.researchandmarkets.com/reports/2228929/
Brochure More information from http://www.researchandmarkets.com/reports/2228929/ Gastric Cancer Description: Gastric cancer (GC) is one of the most common malignancies in terms of incidence and the secondMore information
New Mid-Term Business Plan Sunrise 2012
New Mid-Term Business Plan Sunrise 2012 CHUGAI PHARMACEUTICAL CO.,LTD. President and CEO Osamu Nagayama January 30/31, 2008 Forward Looking Statements This presentation may include forward looking statementsMore information
Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventionsMore information
Pharmaceuticals Division sales up 4%, driven by oncology (HER2-positive breast cancer medicines,
Media Release Basel, 28 January 2015 Roche delivers solid results in 2014 Group sales up 5% at constant exchange rates 1, 1% in Swiss francs Pharmaceuticals Division sales up 4%, driven by oncology (HER2-positiveMore information
NINESIGMA WHITE PAPER OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY How six leading healthcare companies are leveraging Open Innovation to achieve their innovation goals By: Stephen Clulow, DirectorMore information
Healthcare Solid performance, strong perspectives Siemens Capital Market Day Berlin, December 9, 2014
Hermann Requardt Member of the Managing Board & Healthcare CEO Healthcare Solid performance, strong perspectives Siemens Capital Market Day Notes and forward-looking statements This document contains statementsMore information
Innovation, Speed and Growth: Hoffmann-La Roche in the Pharmaceutical Industry
Innovation, Speed and Growth: Hoffmann-La Roche in the Pharmaceutical Industry CPM spoke recently with Ronnie Miller about how Hoffmann-La Roche stays on the cutting edge of the industry, and about Hoffmann-LaMore information
Dr Paul Mundill Innostics Innostics Oy
Dr Paul Mundill Innostics Oy Future Diagnostics Finland Ideas for Query 2009 The aim was to assess the future directions and needs of the Finnish in vitro diagnostics industry and to collect foresightsMore information
Committed to innovation and growth
Committed to innovation and growth Alan Hippe, CFO Roche Group London, September 2012 This presentation contains certain forward-looking statements. These forward-looking statements may be identified byMore information
Global outlook: Healthcare
Global outlook: Healthcare March 2014 healthcare 1 Today s presenters Ana Nicholls Managing Editor, Industry Briefing Economist Intelligence Unit Lauren Brayshaw Marketing executive Economist IntelligenceMore information
Avastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leadingMore information
Roche Holding Ltd, Basel Financial Statements
Roche Holding Ltd, Basel Financial Statements Roche Finance Report 2010 151 Roche Holding Ltd, Basel Financial Statements Income statement in millions of CHF Year ended 31 December 2010 2009 Income IncomeMore information
If you were diagnosed with cancer today, what would your chances of survival be?
Q.1 If you were diagnosed with cancer today, what would your chances of survival be? Ongoing medical research from the last two decades has seen the cancer survival rate increase by more than 40%. HoweverMore information
Midyear Presentation 2013. market strategy
Midyear Higher order Results intake, Presentation lower profitability 2013 focused market strategy THE SAFE HARBOR STATEMENT UNDER THE US PRIVATE SECURITIES LITIGATION REFORM ACT 1995 This presentationMore information
Background and Company Performance... 3. Industry Challenges... 3. Product Family Attributes and Business Impact... 3. Conclusion...
Contents Background and Company Performance... 3 Industry Challenges... 3 Product Family Attributes and Business Impact... 3 Conclusion... 5 Significance of Product Leadership... 6 Understanding ProductMore information
Media Release. Solid overall results. Basel, 2 February 2011
Media Release Basel, 2 February 2011 Solid overall results Mid-single digit sales growth in local currencies excluding Tamiflu Strong profit growth Promising late stage pharmaceutical pipeline of twelveMore information
Roche delivers strong performance in the first half of 2015
Media Release Basel, 23 July 2015 Roche delivers strong performance in the first half of 2015 Group sales up 6% at constant exchange rates 1, 3% in Swiss francs Pharmaceuticals Division sales up 5%, drivenMore information
Innovation in the Pharmaceutical Industry Future Prospects
r Innovation in the Pharmaceutical Industry Future Prospects Talk by Dr Franz B. Humer, Chairman of the Board of Directors and CEO of F. Hoffmann-La Roche Ltd, to the Zürcher Volkswirtschaftliche GesellschaftMore information
Biotest Group. H1 2014 Conference call 12 August 2014
Biotest Group H1 2014 Conference call 12 August 2014 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assetMore information
REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC MarketsMore information
M I N U T E S. The Chairman of the Board, Dr Christoph Franz, opened the meeting at 10.30 a.m. and took the chair.
M I N U T E S of the 98th Annual General Meeting of the Shareholders of ROCHE HOLDING LTD, Basel held at 10.30 a.m. on 1 March 2016 at the Convention Centre, Basel Trade Fair Complex, Basel (TranslationMore information
Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd.
Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Oncology Strategy and Acquisition Significance 1 Commitment to Oncology Entering the Oncology Area Globally ExternalMore information
MOLOGEN AG German Equity Forum 2015
German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapiesMore information
Table of Contents. Key figures 3
Key figures 3 Group and Divisional Results 4 Overview 4 Pharmaceuticals 5 Diagnostics 7 Vitamins and Fine Chemicals 7 Group operating results 8 Financial income 8 Cash flows 8 Financial condition 9 OutlookMore information
Roche Position on Human Stem Cells
Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along withMore information
Investors/Analysts Conference London, July 2010 Ian Bishop
Investors/Analysts Conference London, July 2010 Ian Bishop This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects,More information
Orphan Pharma: pathfinders for an increasingly specialised industry
Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialtyMore information
Investors/Analysts Conference London/New York, February 2012 Ian Bishop
Investors/Analysts Conference London/New York, February 2012 Ian Bishop This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such asMore information
Monoclonal antibody (mab) products are currently a fast
Antibody Monoclonal Therapeutics Janice M. Reichert, Ph.D. Monoclonal antibody (mab) products are currently a fast growing category of drugs. Like antibodies produced naturally by the human immune system,More information
omas Kudsk Larsen, Head of Investor Relations North America, Vice President
Roche: Bank of America/Merrill Lynch 2014 Health Care Conference, Las Vegas, 14 May omas Kudsk Larsen, Head of Investor Relations North America, Vice President Forward-looking statements This presentationMore information
We Innovate Healthcare
Part 1 Roche Annual Report 2007 Business Report We Innovate Healthcare We Innovate Healthcare As a research-intensive healthcare company, Roche discovers, develops and provides innovative diagnostic andMore information
Richard T. Clark Chief Executive Officer and President. Executing on Our Strategy
Richard T. Clark Chief Executive Officer and President Executing on Our Strategy Merck s Plan to Win: Preparing for Our Future Success BECOME THE MOST TRUSTED INDUSTRY LEADER IN DELIVERING VALUE TO CUSTOMERSMore information
Personalised Healthcare Frequently Asked Questions
Personalised Healthcare Frequently Asked Questions Foreword In one sense, personalised healthcare is nothing new. It is what doctors have aimed to provide for their patients through the exercise of theirMore information
Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups
Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed toMore information
A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field
A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field Introduction The field of regenerative medicine remains at the forefront of personalized medicine and healthcareMore information
Biotherapeutic Medicines
International Federation of Pharmaceutical Manufacturers & Associations Biotherapeutic Medicines Grasping the New Generation of Treatments Biotherapeutic medicines are an integral and valuable part ofMore information
*See note 4 to our Summary Financial Information table below concerning our current operational and reporting structure
INTERIM REPORT 1(39) Nokia Corporation Interim Report for Q1 2014 FINANCIAL AND OPERATING HIGHLIGHTS First quarter 2014 highlights for continuing operations*: Nokia s non-ifrs diluted EPS in Q1 2014 ofMore information
Global Monoclonal Antibodies Pipeline Insight 2015
Brochure More information from http://www.researchandmarkets.com/reports/3113388/ Global Monoclonal Antibodies Pipeline Insight 2015 Description: Ever since the Nobel Prize was bestowed on the person whoMore information
IMI2: why, what, how?
IMI2: why, what, how? The Right prevention and treatment, to the right patient, at the right time Isabelle Thizon-de Gaulle VP, Strategic initiatives & Scientific relations Sanofi R&D Innovative MedicinesMore information


text:
NCEER-88-0016 | 6/15/1988 | 170 pages
TOC: The table of contents is provided.
Keywords: Seismic Hazard Analysis, Reinforced Concrete Structures, and Earthquakes - Eastern United States.
Abstract: The main objective of this research is to determine the seismic hazard associated with reinforced concrete structures in the eastern United States. The structures considered are medium to high rise, and are designed without consideration of seismic loading. Damage is quantified as an index which can be used to determine whether the structure is reparable, severely damaged, or collapsed. The structural damage is calculated using comprehensive inelastic dynamic analysis. For this study, a Monte Carlo simulation approach has been chosen with simulated earthquake motion developed from spectral characteristics of earthquakes typical to eastern North America. The study considered three similar test structures to determine the damage level associated with different types of designs. Two of the structures considered were frame type structures, one structure was a "weak beam" design, and the other was a "weak column" design. Additionally, a coupled frame shear wall structure was considered to determine the effect of the shear wall on the resulting damage index. Monte Carlo simulations were performed for earthquakes with a variety of magnitudes and epicentral distances. The results of the simulations provide mean and expected maximum overall damage indices of the structures for each combination of magnitude and distance covered. Empirical equations were then developed to define the resulting damage as a function of magnitude and epicentral distance.

subset: commoncrawl


text:
|Oral focal mucinosis: Review of the literature and seven additional cases.
MedLine Citation:
|PMID: 21466997 Owner: NLM Status: In-Data-Review
|Oral focal mucinosis (OFM) is a rare, asymptomatic, benign lesion of unknown etiology that usually involves the mandibular gingiva. This article reports on seven patients, six of whom had lesions that involved the gingiva and one that involved the palate. All cases demonstrated the classic lobular, myxomatous mesenchymal tissue with stellate cells. In all cases, immunohistochemical staining for S-100-protein expression was negative, thus excluding the principal differential diagnoses of myxoid neurofibroma and neurothekeoma (nerve sheath myxoma). This article seeks to bring OFM to the attention of clinicians and pathologists who must consider the differential diagnosis of gingival and palatal nodules.
|Nagamani Narayana; John Casey
Related Documents :
|21119957 - Epidemiology of orofacial clefts in africa: methodological challenges in ascertainment.
16682877 - Female monozygotic twins with selective mutism--a case report.
18263837 - Cephalopagus conjoined twins in a leopard cat (prionailurus bengalensis).
3609847 - Palatal "myoclonus" and inferior olive hypertrophy with one-sided cerebellar lesion. cl...
17155997 - Congenital, ill-defined, yellowish plaque: the nasal dermoid.
25148817 - Insulinoma in a young female patient with systemic lupus erythematosus: a case report.
Publication Detail:
|Type: Journal Article
Journal Detail:
|Title: General dentistry Volume: 57 ISSN: 0363-6771 ISO Abbreviation: Gen Dent Publication Date: 2009 Mar-Apr
Date Detail:
|Created Date: 2011-04-06 Completed Date: - Revised Date: -
Medline Journal Info:
|Nlm Unique ID: 7610466 Medline TA: Gen Dent Country: United States
Other Details:
|Languages: eng Pagination: e11-3 Citation Subset: D
Export Citation:
|APA/MLA Format Download EndNote Download BibTex
|MeSH Terms
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treatment of severe localized periodontal destruction associated with a cemental tear: A case report...
Next Document: Interdisciplinary treatment of multiple maxillary anterior diastemas: Case report.


text:
Press Contact ::
General Questions:
Press Inquiries:
Artist Relations:
Daisy Rock Artist Janet Robin Presents a Brand New Daisy Rock Red Hot Red Heartbreaker Guitar at the "Arts for Kids" Show in Mayfield, NY
Daisy Rock Artist Janet Robin, L.A based singer, songwriter and guitarist who has played with Lindsey Buckingham (Fleetwood Mac) and Meredith Brooks, presented 9-year-old Nicole Oeser of Schenectady, NY with a brand new Daisy Rock "Red Hot Red" Artist Series Heartbreaker guitar at the "Arts For Kids" show at the Mayfield School in Mayfield, NY.
"Arts For Kids" is a summer series presented by the First Presbyterian Church of Broadalbin, NY and made possible with funds from the Decentralization Program, a regrant program of the New York State Council on the Arts administered by the Schoharie County Arts Council. Daisy Rock is pleased to be a part of this great event. Congratulations again, Nicole!!!
(PHOTO: Doug Sieg)


text:
Abstract and Applied Analysis
Volume 2013, Article ID 270191, 12 pages
Complex Dynamics of a Diffusive Holling-Tanner Predator-Prey Model with the Allee Effect
Faculty of Science, Shaanxi University of Science and Technology, Xi'an, Shaanxi 710021, China
Received 2 August 2012; Revised 9 December 2012; Accepted 21 December 2012
Academic Editor: Lan Xu
Copyright © 2013 Zongmin Yue et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We investigate the complex dynamics of a diffusive Holling-Tanner predation model with the Allee effect on prey analytically and numerically. We examine the existence of the positive equilibria and the related dynamical behaviors of the model and find that when the model is with weak Allee effect, the solutions are local and global stability for some conditions around the positive equilibrium. In contrast, when the model is with strong Allee effect, this may lead to the phenomenon of bistability; that is to say, there is a separatrix curve that separates the behavior of trajectories of the system, implying that the model is highly sensitive to the initial conditions. Furthermore, we give the conditions of Turing instability and determine the Turing space in the parameters space. Based on these results, we perform a series of numerical simulations and find that the model exhibits complex pattern replication: spots, spots-stripes mixtures, and stripes patterns. The results show that the impact of the Allee effect essentially increases the models spatiotemporal complexity.


text:
TORONTO (Reuters) - Canada's benchmark stock index held on to gains to close slightly higher on Tuesday as resurgent gold prices boosted mining stocks and investor optimism grew on prospects for European bond-buying.
The Canadian market followed European markets higher, but was more subdued given the heavy weighting of commodity-related stocks that get most of their momentum from signs of growth in the world's emerging economies, such as China.
"It's grinding its way slowly upward here," said Douglas Davis, chief executive officer at wealth management firm Davis-Rea. "Nothing spectacular, but I think it will continue to do that for the next couple of months unless something really blows up."
The price of gold jumped to its highest level since May, and gold miners were among the top-weighted upward movers on the Toronto exchange, led by Goldcorp Inc's (G.TO) 2.5 percent rise to C$38.88 and Eldorado Gold Corp (ELD.TO) jumping 5.7 percent to C$12.43. <GOL/>
In fact, four of the top five performers by market weight were gold miners, who Davis said have been able to break out of a technical trading zone on the back of the rising price of bullion.
The Toronto Stock Exchange's S&P/TSX composite index .GSPTSE unofficially closed up 40.89 points, or 0.34 percent, at 12,116.92. During the session, it had risen as much as 1 percent.
The broad gains in Canadian stocks followed European listings higher as investors bet on political and monetary moves to backstop the region's most debt-ridden countries.
Italy's main index closed 2.4 percent higher, while Spain and France both added 1.1 percent.
Philip Petursson, director of the portfolio advisory group at Manulife Asset Management, said a string of decent corporate earnings this month and attractive valuations had given the exchange a positive tilt which could only be aided by European optimism.
"The glass is half full and if things in Europe seem to be leaning a little bit more positively, that's just further upside," he said.
European shares earlier hit a 13-month high and the euro climbed amid hopes that meetings on Greece's future this week and new crisis plans being drawn up by the European Central Bank will soothe the euro zone's ongoing debt crisis.
Reporting by Alastair Sharp, editing by Gary Crosse


text:
You might not think that energy and cutting edge science go together. But they do.
Cramer says they're very closely linked.
It's because of scientific breakthroughs that energy companies are able to extract oil and nat gas from places that were completely inaccessible just a short time ago.
Also, because of new science, fields that were considered extremely mature now promise to yield enough energy to sustain our nation for many, many years to come.
Cramer believes these advances are significant they could lead to widespread prosperity and energy independence in North America as soon as 2020.
And at the epicenter of this theme sits Core Labs.


text:
Duff, Haylie
Haylie Duff, sister of Hilary Duff, made her film debut in Napoleon Dynamite and is rumored to have had a rhinoplasty (nose job) and genioplasty (shaved chin).
Did Hilary Duff's Sister Haylie Duff Get Plastic Surgery?
The following article is reprinted from Make Me Heal's Celebrity Plastic Surgery News. The article, along with photos can be found at the following link: Haylie Duff Plastic Surgery?.
Since making her film debut in the surprise hit Napoleon Dynamite, Haylie Duff has come under a lot of fire for not looking as good as her little sister, former Disney diva Hilary Duff. Makemeheal.com suspects Haylie of getting plastic surgery in order to look as cute as her little sister.
24-year old Haylie Duff may not be the talented powerhouse her little, and more popular, sister Hilary Duff is. But she may be trying to come close with the help of some plastic surgery.
Part of Hilary's cuteness comes from her small, round face and tiny nose. While Haylie bears a resemblance to her sister, her features are much larger and more pronounced. According to some recent rumors floating around the Net's hottest gossip sites, Haylie may have tried to rectify this recently, by getting her nose and chin done.
Haylie's new nose seems to be smaller, thanks to a well done rhinoplasty. Her chin is also rumored to have been shaved down with a genioplasty. Her new nose and chin help give her a softer, more feminine look.
Plastic surgeon Dr. Sherrrell J. Aston says, "Haylie Duff, often referred to as Hillary Duff's sister, is following the steps of Jessica and Ashlee Simpson. We have seen the scenario played out before; one "prettier" sister who is more successful than the other quirkier sister, that is, until the other one has plastic surgery! Just like Ashlee Simpson, Haylie Duff has recently had a rhinoplasty and chin surgery. She looks great and is settling into her new look. In my opinion the surgeon did an excellent job balancing Miss Duff's proportions. She does not look overly altered, just a better version of herself. I wish her the best of luck with her career."
Haylie hasn't been in the spotlight lately, which could be because she is recuperating from her recent procedures. Or it could be because the paparazzi are more focused on bigger stars.
Plastic surgeon Dr. Jennifer Walden says, "Haylie Duff does appear to have undergone rhinoplasty as her nose now appears to be much smaller, straighter and in better alignment with the rest of her features. It also looks as if she has had a reduction genioplasty (surgery to lessen the size of the chin) given that it is much less pointy. It is hard to tell the extent of her work at this time as she has likely had the procedures somewhat recently."
New York plastic surgeon Dr. David Shafer says, "Haylie certainly appears to have had a chin implant and rhinoplasty. In comparing the photos, her chin projection is greater and the profile of her nose has changed."
On the other hand, what seems to be plastic surgery could just be a more flattering camera angle or tilt of the head that helps to deemphasize Haylie's more prominent features.
Dr. Paul S. Nassif, a Facial Plastic and Reconstructive Surgeon and Rhinoplasty Specialist in Beverly Hills, Calif., said, "I don't believe Haylie Duff has had any work done. By smiling in the picture on the left, it makes her nose and chin stick out, which is a contrast to the other profile picture."
Whether or not Haylie has actually been under the knife is irrelevant, as she is once again following in her little sister's footsteps. Hilary has already come to Make Me Heal's attention for possibly going under the knife to have a breast augmentation. (See Make Me Heal's story on Hilary Duff's breast implants).
While Haylie may not have been on the big screen lately, she's been on TV and can likely be found on red carpets for various events.
Plastic Surgery Message Boards
Talk about plastic surgery with people and doctors on Makemeheal.com's Plastic Surgery Message Boards.
Plastic Surgery Before/After Pictures
View Plastic Surgery Before/After Pictures.
Find Top Doctors In Plastic Surgeons Directory
Find top plastic surgeons in the Plastic Surgeon Directory.
Ask Plastic Surgeons Questions Live
Ask Plastic Surgeons Questions & Get Answers.
Shop For Plastic Surgery Recovery Products
Shop for Plastic Surgery Recovery Products.
Should I Get Plastic Surgery?
Upload your before Plastic Surgery Photos to get feedback from doctors and people if you would be a good candidate for plastic surgery.


text:
NCAA Basketball Odds & StatsLive Daily NCAAB Odds |Today's Game Prop Bets
Scoreboard | Matchups | Previews
Trends Sheet | Off. Rankings | Def. Rankings
Hot And Not | Game Recaps
Standings | Schedules | Game Logs | Teams Info
2018-19 NCAA College Basketball Odds
ncaab Preview
Florida Gulf Coast Eagles vs. Oklahoma State Cowboys
The Florida Gulf Coast Eagles and the Oklahoma State Cowboys will both be gunning for a victory on Tuesday when they meet at Gallagher-Iba Arena.
Oddsmakers opened the Cowboys as -13.5-point favorites versus the Eagles, while the game's total opened at 161.
In their last action, Oklahoma State was a 82-68 loser on the road against Jayhawks. They failed to cover the +6-point spread as underdogs.
Florida Gulf Coast lost its last outing, a 108-96 result against Bison on March 04. They failed to cover in that game as a -6.5-point favorite.
Florida Gulf Coast:
Team record: 23-11 SU,7-4 ATS
Oklahoma State:
Team record: 19-14 SU,16-15 ATS
Oklahoma State is 5-1 ATS in its last 6 games
Oklahoma State is 4-2 SU in its last 6 games
The total has gone UNDER in 4 of Oklahoma State's last 5 games


text: Edgewater is located in the county of Anne Arundel. Services related to wedding supplies, website designing, truck repairing, repair of television and radio, telecommunication, storage and self service, roadside, relocation, pet sitting, shipping and financial advisory, continue to serve the growing community of Edgewater. Commercial spaces are utilized by aircraft maintenance facility, financial institutions, boat repairing facilities, clinics, clubs, manufacturing site of computer peripherals, drug stores, public golf courses facilities, machine shops and seafood restaurants.


text:
'Giftgram' is a user-friendly app that makes it easy for users to send gifts to friends and family via text message. With no need to visit busy malls or spend time lining up at the post office, this app helps to simplify the gift-giving process.
Giftgram works by highlighting a list of curated gifts from both local and international retailers. To begin, users browse through the different categories to find an appropriate gift. After choosing the perfect item, users simply select a recipient from their existing contact list. The recipient will immediately receive a text-message or email asking for their shipping address. Once the recipient has filled in their information, the gift will arrive in just three to five days. As a result, finding and giving the perfect gift becomes as easy as sending a text message.
Giftgram is perfect for busy consumers who are looking for a way to give gifts that are thoughtful and unique, without the hassle of shopping around.
Text-Based Gifting Apps
More Stats +/-
Social Gifting Apps
Beer-Gifting Apps
Effortless Gifting Apps
Refreshment-Gifting Apps
Customizable Gifting Apps
Free 2019 Report & eBook
Get the top 100 trends happening right NOW -- plus a FREE copy of our award-winning book.
Our Research Methodology
This article is one of 350,000 experiments. We use crowd filtering, big data and AI to identify insights.
The Giftgram App Makes It Easy to Shop for the Perfect Present
- By: Katherine PendrillMay 3, 2016
References: play.google & gif
References: play.google & gif


text:
Empowering you and your school
To support you and your staff in working to the best of your abilities, the Schools HR team provides extensive training opportunities, either at your school or in our fully-equipped training rooms at Francis House.
Working closely with your leadership team, NPW will develop a tailored training programme in response to the needs of your school, delivering anything from one-to-one coaching to skills workshops.
Our HR Training programme includes:
- >Safer recruitment training
- >Sessions for school staff on recruitment and payroll issues
- >Sessions for governors, headteachers and senior staff on HR procedures, e.g. disciplinaries, sickness management, grievances, employment tribunals
- >Training for NQT Induction Tutors
- >Sessions for governors on safer recruitment, appointing senior leaders and performance management


text: We specialized in Custom T-shirts, Full Bleed Sublimation Printing, Unique Gifts and Personalized Product using our printing services like Digital Printing, Embroidery and Silkscreen. We are found in 2009 and delivers products such as Custom T shirts, Unique Gifts and Personalized Products. There are two way to order kindly choose which method:You can order through our website at www.transferit.com.ph or by sending us a message with your details on 6323283070


text:
The MGH/Harvard Cutaneous Biology Research Center (CBRC) was established in 1989 by a multi-year support agreement between MGH/HMS and the Shiseido Co. Ltd. to conduct research on the skin and its adnexa using molecular biology techniques from multidisciplinary areas.
The research interests of the principal investigators cover a wide variety of areas, and a number of biological systems are used including mice, chicken, frogs, fruit flies, yeast, and various cell culture systems.
The research programs within the CBRC are diverse and include:
Other programs include studies of the attachment of the epidermis to the dermis mediated by the basement membrane zone as a means of understanding the blistering diseases of man, wound healing, and skin aging; and the control of skin pigmentation and erythema in the human body through the study of the effect of Maxidilan, a potent vasodilator. Investigators gain an understanding of the immune system generally and in the skin by studies of the development of lymphoid cell system from multipotent hemopoetic stem cells.
Additionally, the functional aspects of chromatin templates to recreate the natural mechanisms of gene activation and expression are being explored. Other studies relate to the role of transcription factors that are involved in cancer and melanogenesis through the identification of novel factors using the yeast-two-hybrid system.Learn more >


text:
Most people take a photo of the Education Resource Centre on the left to represent UTown, so I thought I'd do something different and include the Residence blocks on the right too.
- Nikon D600, 28-300mm f3.5-5.6
- At 28mm, f4, ISO 3200, 1/15 seconds
- Manual exposure, center-weighted metering, auto White Balance
- Picasa: Straighten, crop, auto contrast, glow.
Time is 7:36pm, rich color in the sky. A few minutes later and the photos I took had a black sky. I was photographing a school debate and finished just at the right time.


text:
Bug #1937
vnconfig and swapfile
probably there is something wrong or obsolete in:
lap# truncate -s700M /dati/swapfile
lap# chmod 0600 /dati/swapfile
lap# vnconfig -e vn0 /dati/swapfile swap
vnconfig: swapon: Device not configured
lap# vnconfig -l
vn0: covering /dati/swapfile on ad0s2h, inode 409
vn1: not in use
vn2: not in use
vn3: not in use
lap# ls /dev/vn*
/dev/vn /dev/vn0s0 /dev/vn2
/dev/vn0 /dev/vn1 /dev/vn3
lap# swapon /dev/vn0
swapon: /dev/vn0: Device not configured
lap# swapon /dev/vn0s0
swapon: /dev/vn0s0: Device not configured
Best wishes, \ferz
#1 Updated by thomas.nikolajsen almost 8 years ago
The link is to the old handbook, but problem is the same in new handbook;
will update it.
For the time being vnconfig(8) can't add swap file directly;
you will have to add vn file, label and do swapon(8), e.g.:
# vnconfig -c vn0 /dati/swapfile
# disklabel -rw vn0s0 auto
# disklabel -e vn0s0 # add b: * * swap
# swapon /dev/vn0s0b
#2 Updated by swildner over 3 years ago
- Description updated (diff)
- Status changed from New to Closed
Setting up a swapfile just via vnconfig(8) does in fact work here (4.3 master), therefore I'm closing the issue.
advancer# truncate -s700M swap
advancer# vnconfig -e vn0 swap swap
advancer# swapinfo -k
Device 1K-blocks Used Avail Capacity Type
/dev/da0s1b 67108864 32 67108832 0% Interleaved
/dev/vn0 716800 0 716800 0% Interleaved
Total 67825664 32 67825632 0%
It can also be configured via rc.conf:
I don't know what was wrong at the time this bug was filed.


text:
Clifton Park
There aren't many bands better at songcraft than Spoon. Throw on any of the Austin, Texas-based indie rockers' nine studio albums, and it's obvious that the group puts a lot of thought behind each song's structure.
This commitment to detail also carries over into Spoon's live show, as evidenced by Tuesday night's performance at Upstate Concert Hall. In front of an enthusiastic, sold-out audience, Spoon provided a 95-minute snapshot of its two-decade career that upped the volume and added some more guitar, while utilizing one of the best sound mixes I've ever heard at the venue to maintain the band's musical nuances and textures.
Spoon opened with current single "Do I Have to Talk You Into It?," nailing the tune's slinky, midtempo synth-and-bass groove. After a brief greeting from frontman Britt Daniel, the band played a lights-out version of "Inside Out" before kicking it up a notch with "I Turn my Camera On." Live, this song was transformed from falsetto-voiced soul rock into more of a robot-rocker, like a grimier take on Bowie circa '76 that the crowd went wild for.
In a recent interview with the Times Union, Spoon drummer Jim Eno mentioned two songs that he particularly has enjoyed playing on the current tour: "Don't You Evah" and "I Ain't the One." Spoon played both, and Eno's enthusiasm was evident, with the band maintaining the studio versions' delicate beauty and structure, but his drumming was more urgent, giving each a little extra rhythmic drive.
"Can I Sit Next to You" was still a sensual jam, but the band stretched it out with a wild, extended, keyboard-laden outro. After a couple of more tunes, Spoon played one of its biggest hits, "The Underdog." Of everything the group played, this one sounded most different in the live setting. Gone were the acoustic guitars and the horns, replaced by electric guitar and keyboards. This changed the song's essence from a somewhat precious indie-pop gem to more of a power-pop tune. That change in style didn't change audience reception, as it was one of the best-received songs of the evening, and Daniel was able to engage fans in a singalong with minimal prompting.
The night closed with a closing one-two punch of "Hot Thoughts" and "Rent I Pay." The former featured a little more riffage than its bass- and synth-laden original take, but it still smoked, and the latter ended the show with raucous energy.
More Information
Concert review
Spoon with White Reaper
When: 8 p.m. Tuesday
Where: Upstate Concert Hall, 1208 Route 146, Clifton Park
Length: Spoon 95 minutes; White Reaper 45 minutes
The crowd: Sold out and enthusiastic
Speaking of raucous energy, opening act White Reaper was full of that. The Louisville, Ky., band answered the (probably) previously unasked question of what it would sound like if Thin Lizzy got all hopped up and utilized four-on-the-floor drumming. Songs like "Little Silver Cross," "Sheila" and "World's Best American Band" rocked hard and were abundant fun. The last tune is also the name of White Reaper's 2017 album, one that earned rave critical reviews. Between that and the quality of its live performance, it's a band worth getting to know.Read Full Article
Jim Shahen Jr. is a frequent contributor to the Times Union.


text: Changing your primary email address Javier Vegas March 07, 2016 17:58 Follow Your primary and sign-in email address is the address you use to sign in to your BigTent group as well as the email address at which you receive group announcements and forum messages. Changing your primary email address is a quick, three-step process: 1. Sign in to www.bigtent.com with your old email address. Go to [your name] > Settings, click "change" next to your email address. Click "Add another email address" and enter your new email address in the box. Click "Add 2. We'll send an email to your new address so that you can verify it. Please note: The email comes from firstname.lastname@example.com, so please check your spam or junk folder if you have difficulty finding it. 3. Click the link provided in the confirmation email to verify your new address. You'll be taken to back to your BigTent "Contact Information" page. Click "make primary" next to your new email address. You'll need to enter your password for security reasons. Once you add a new primary email address, you'll also have the option to remove your old email address. Remember that after you change your primary email address, you'll need to use this address to sign in to BigTent.


text:
Commonwealth Games gold medallist Mohammad Ali Qamar kept Indian hopes alive by progressing to the semi-finals with a slender one point win over Bilali Suleiman Wanjau of Kenya in the light-fly quarter-finals of the Afro-Asian Games boxing tournament on Saturday night.
Another Indian to bring cheer to the country was Ramanand, who emerged a runaway winner in the light-weight quarter-final.
Ramanad crushed Bongani Mahlangu of South Africa 26-8.
Qamar, who survived a solid onslaught from the hard-hitting Wanjau, a quarter-finalist in the 2000 Sydney Olympics, prevailed 14-13 in the end.
In the semi-finals, Qamar will meet Endelkachew Kebede of Ethiopia, who received a bye to the last four stage, while Ramanad clashes with Bak Jong-Su of Korea, an Asian Games gold medallist.
The Korean advanced without much sweat as Ethiopian Esayas Getaneh retired in the first round.
The Kolkata-based Qamar could not get into his rhythm in the first round and the Kenyan was quick with his mixture of both left and right punches.
However, Qamar was at his best in defending and at the fag end of the first round, effected a cut on the Kenyan's left cheek.
Midway into the second round, Qamar started his charge and earned points. The Indian moved swiftly and used his left hand more often. He maintained a slight edge in the third round too and once came up with a superb right jab to the face of Wanjau. Qamar looked tired in the fourth round but still defended well.
In another light-fly bout, Harry S Tanamor of The Philippines, a bronze medallist in the World Cup and silver medal winner in the Asian Games, won a one-sided fight against Joseph Hilongwa Jermia of Namibia 21-10.
Following are the other quarter-final results:
Light-fly: Serik Sikymbayev (Kaz) bt Jolly Kalongole (Uga) 23-18.
Light-weight: Dilshod Mahmudov (Uzb) bt Ahmed Sadiq (Ngr) 6-2.
Middle-weight: Nabil Kassel (Algeria) bt Yerbol Dutbayev (Kaz) 27-11; Utkirbek Hayarov (UZB) bt Daniel Nyambwena Shisia (Ken) 18-10.


text:
A double panel and a seminar hosted by Theory Talks & Millennium
during the 2012 Annual Millennium Conference
October 20-22 2012, at the London School of Economics
Conveners: Rocco Bellanova, Julien Jeandesboz, Peer Schouten
Technical devices such as algorithms, databases, and robots mediate the production of (in)security and the conduct of war; 'non-places' such as financial markets remap and reshape the exercise of state sovereignty; previously established distributions such as between 'private' and 'public' entities are increasingly entangled in hybrid assemblages. These and other heterogeneities of the international are part of a renewed focus on materialities and material practices in international relations (IR).
World politics is thus increasingly recognized as involving the participation of multiplicities of heterogeneous elements, many of which were until now smoothened out in mainstream IR accounts. When IR researchers shift their analytical lenses, they bring into focus agencies and practices that actively contribute to the assembling of the international—in doing so, they intervene in, and reformulate some of, IR's most classical concerns. Point of departure for this workshop is that dealing with such seemingly new world politics, and accounting for these constitutive heterogeneities, however remains a difficult challenge.
Aim of the event
The main goal of the event is to bring together researchers that, in different ways, depart from an understanding of IR premised on homogeneity and engage with entanglements and multiplicities that go beyond rational choice and inter-subjective social constructions. The ambition is to foster debates and exchanges on shared concerns with accounting for heterogeneities in the international. In particular, the aim of this event is to bring to the fore the potentialities and pitfalls of working with 'thinking tools' that hail from beyond the traditional disciplinary horizons of IR, such actor-network-theory (ANT), science, technology and society studies (STS), or performance theories.
Further information can be found here.


text:
jQuery's animations are actually performed by the
animate() method. Let's start with a simple HTML structure:

with the following styles:
#container { width: 400px; height: 100px; } .left { background: orange; width: 100px; height: 100px; float: left; position: relative; } .right { background: yellow; width: 100px; height: 100px; float: right; position: relative; }
We want the two floated elements exchange their position within their container. The jQuery code is really simple:
$(document).ready(function() { $('#animate').click(function() { $('.left').animate({left: '300px'}, 'slow'); $('.right').animate({right: '300px'}, 'slow'); return false; }); });
The offset for the animation is given by the subtraction of the overall width of the container minus the width of each box.
The second parameter determines the speed of the animation (in this case is
slow). Optionally the
animate() method accept a callback function to be executed as the third parameter when the animation is complete. You can see the final result


text:
Has anyone taken Tramadol 12 hour release tablets? I've been put on them and they make me so itchy to point I'm scratching my head in the half asleep and ripping hair out in the process and also making my skin red raw! I need some advice because I'm going insane I wouldn't mind if it was for a short period but it's for like 4 to 5 hours at a time!
Love you all!
Louise x


text:
Jump to: Concordance • Thesaurus • Library • Subtopics • Terms
Enterprise of Gainas, the Gothic Barbarian. Evils which He ...
Maximinus Cæsar Having Come at that Time into the Government...
Acts XXV
Matt. xxvi. 6, 7
ThesaurusChiliarchs (4 Occurrences)
... Multi-Version Concordance Chiliarchs (4 Occurrences). Mark 6:21 And a holiday
being come, when Herod, on his birthday, made a supper ...
/c/chiliarchs.htm - 7k
Chiliarch (17 Occurrences)
Chilion (3 Occurrences)
Grandees (1 Occurrence)
Distinction (14 Occurrences)
Audience (17 Occurrences)
Holiday (5 Occurrences)
Bible ConcordanceChiliarchs (4 Occurrences)
Mark 6:21 And a holiday being come, when Herod, on his birthday, made a supper to his grandees, and to the chiliarchs, and the chief men of Galilee;
Acts 25:23 On the morrow therefore, Agrippa being come, and Bernice, with great pomp, and having entered into the hall of audience, with the chiliarchs and the men of distinction of the city, and Festus having given command, Paul was brought.
Revelation 6:15 And the kings of the earth, and the great, and the chiliarchs, and the rich, and the strong, and every bondman and freeman, hid themselves in the caves and in the rocks of the mountains;
Revelation 19:18 that ye may eat flesh of kings, and flesh of chiliarchs, and flesh of strong men, and flesh of horses and of those that sit upon them, and flesh of all, both free and bond, and small and great.
Related Terms
LinksBible Concordance • Bible Dictionary • Bible Encyclopedia • Topical Bible • Bible Thesuarus


text:
Was there for 3 nights and can say only, Thanks to Matteo and his mother for the wonderful experience! Very clean place, comfortable beds and good location. If I go to Milano again, definitely this will be my choice again. Forca Inter :)
"Remember to take Italian adaptor which is not same as European - though the family sorted our problem out..."


text: OK, so I have a problem that's got me pulling out my hair. I have a Keynote presentation (for an upcoming job interview, thus the stress) which contains a number of .pdf images. These were mainly generated using Illustrator CS2, from output of a mathematics package. These .pdf images are now randomly corrupted. For instance, the axis of one plot will be garbled, while the other is fine, and the axis labels are fine. Or, some extra text inserted into the body of the plot disappears, while the rest is OK. Now, what's got me confused is the random nature of this process. For instance, it was fine at first, but after saving, quitting, and reopening, it was corrupted. Save as, open again, and now it's OK. But, different things are corrupted. Basically it's hit or miss each time I open it. Also, I can have two versions of this presentation open at once, called v1 and v2. Some things look OK in v1 and some in v2. Now, if I cut out a bad figure from v1, and copy in a good version from v2, the result in v1 is the same. So, I can't just copy/paste over it. Whatever the problem is, it's endemic to the Keynote presentation. Any ideas as to what might be causing this? Are there any known issues with pdf handling? Any programs from Adobe I should uninstall/reinstall? I'd like to get this sorted out quickly, given my upcoming interview. Thanks in advance for the help.


text:
Andre 3000 on Ke$ha's "Sleazy" Remix
Just released, Andre jumped on a remix of Ke$ha's new track "Sleazy" and his verse jumps from baby pictures to marital troubles, to the hood pronunciation of "Ke$ha". Stream it right here and download the track using the link below.
Click here to download Ke$ha's "Sleazy" Remix (Ft. Andre 3000) on iTunes now.


text:
UEFA Euro 2016 France vs Romania Live Stream Score Goals Teams Line Ups Prediction :- Today the UEFA European Championship 2016 are beginning as it is going to be the 15th edition of the prestigious soccer tournament France and Romania teams will compete in the match no. 1 and the whole world is keeping their eyes on this emphatic contest. Unlike the previous editions in this season 24 teams will compete in place of 16 for a place in the final which will happen on 11 July 2016.
France vs Romania Winner Prediction
The Game between France and Romania will not be easy call to predict which team will win the match. Both these football teams have toe to toe players on par with each other. Win Predictor says France are likely to win the crucial first game of the Euro 2016 Cup. There will only be one winner in a game and the best team will take the game. Predicted Score : France 2 – 1 Romania.
But this time around, the match is between two top teams that making a call on who will reach the finish line is tough. A tough call, but France are likely to will this game with some tough effort and with help of home support !
Prediction – France will win today against Romania
France vs Romania Head to Head
Total Games played between the two teams : 15 | France Won : 7 | Romania Won : 3 | Draw : 5.
Last meeting (06 Sep 2011) : France vs Romania : 0 – 0.
UEFA Euro 2016 France vs Romania Lineups
France Squad : Hugo Lloris, Eliaquim Mangala, Moussa Sissoko, Mamadou Sakho, Kurt Zouma, Olivier Giroud, Morgan Schneiderlin, Anthony Martial, Yohan Cabaye, Bacary Sagna, Laurent Koscielny, and Mathieu Debuchy
France Captain : Hugo Lloris
France Manager : Didier Deschamps
Romania Squad : Alexandru Maxim, Vlad Chiriches, Costel Pantilimon, Florin Gardos, Razvan Rat, Steliano Filip, Gabriel Torje, Costel Pantilimon, Ciprian Tatarusanu, Dragoș Grigore, Bogdan Stancu, Constantin Budescu
Romania Captain : Razvan Rat
Romania Manager : Anghel Iordanescu
Match Facts
The live action of Game 1 between Romania vs France will kick off at 9 p.m. CET / 3 p.m. ET, Friday, June 10th 2016. For live action in India the match will kick off at 1:30 AM IST, Wednesday. Set those reminders folks, this will be one tough battle to watch
Game Venue / Stadium : Stade de France – Saint-Denis, France
Capacity Approx : 81,338
In India you can watch the live coverage of France vs Romania UEFA EURO 2016 match on June 11 on Sony SIX at around 12:30 AM Indian Standard Time
Do arrive back here for more updates on UEFA European Championship 2016


text:
Action News has learned that investigators have positively identifed the body of Diane Corado.
Bucks County First Assistant District Attorney Michelle Henry said Corado's remains were found two weeks ago near the north branch of Newton Creek in Camden, New Jersey.
Corado disappeared nearly two and a half years ago after she was abducted from her home in Fairless Hills.
Her ex-boyfriend, Kenneth Patterson, was previously charged with her kidnapping and murder, even though investigators hadn't located her body.
Michelle Henry told Action News investigators found Corado's body after conversations with Patterson.
Patterson remains jailed in Bucks County awaiting trial.
His next court hearing is set for early July.